Literature DB >> 8739653

Prevention of infection in children with acute leukaemia. No major difference between total and selective bowel decontamination.

N Muis1, W A Kamps, J Dankert.   

Abstract

To evaluate the effect of total bowel decontamination (TD) and selective bowel decontamination (SD) in a non-protective environment clinical and laboratory data of children treated for acute leukaemia between 1983 and 1991 were analysed retrospectively. From 1983 until 1989 34 patients [18 acute non-lymphoblastic leukaemia (ANLL) patients, 16 acute lymphoblastic leukaemia (ALL) patients] received TD and 31 patients (8 ANLL patients, 23 ALL patients) received SD from 1987 until 1991. TD consisted of colistin sulphate, neomycin, cephaloridine and amphotericin B orally as well as Orabase and sterilized food, while the patients were nursed in a single room. SD consisted of oral colistin sulphate, neomycin and amphotericin B. Those patients with ANLL were nursed in a single room; patients with ALL were nursed in a single room during remission induction therapy only. All patients except those with ANLL receiving TD received Pneumocystis carinii pneumonia prophylaxis with cotrimoxazole. Because the two groups were heterogeneous for diagnosis and chemotherapy the occurrence of fever (central body temperature at least 38.5 degrees C) and major infections (septicaemia of infections of the deep tissues or organs) were registered during periods of neutropenia (neutrophilic granulocytes < or = 500/mm3 for at least 8 days). Patients on TD had 55 periods of neutropenia, patients on SD 80. Patients on TD had 89.1 periods of fever/100 periods of neutropenia whereas patients on SD had 56.3. Also patients on TD had 27.3 major infections/100 periods of neutropenia whereas patients on SD had 11.3. Major infections predominantly consisted of septicaemia caused by gram-positive bacteria. We conclude that, in this study, TD in a non-protective environment does not offer better protection against major infections that SD in patients with ALL or ANLL.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8739653     DOI: 10.1007/bf01682341

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  42 in total

1.  Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection. A prospective cooperative study of gnotobiotic care in acute leukemia patients. I: clinical results.

Authors:  M Dietrich; W Gaus; J Vossen; D van der Waaij; F Wendt
Journal:  Infection       Date:  1977       Impact factor: 3.553

Review 2.  The utility of protected-environment regimens for the compromised host: a critical assessment.

Authors:  P A Pizzo; A S Levine
Journal:  Prog Hematol       Date:  1977

3.  Use of oral antibiotics in protected units environment: clinical effectiveness and role in the emergence of antibiotic-resistant strains.

Authors:  J Klastersky; L Debusscher; D Weerts; D Daneau
Journal:  Pathol Biol (Paris)       Date:  1974-01

4.  Protective environment for marrow transplant recipients: a prospective study.

Authors:  C D Buckner; R A Clift; J E Sanders; J D Meyers; G W Counts; V T Farewell; E D Thomas
Journal:  Ann Intern Med       Date:  1978-12       Impact factor: 25.391

5.  Increasing incidence of Gram-positive sepsis in cancer patients.

Authors:  P A Pizzo; S Ladisch; R M Simon; F Gill; A S Levine
Journal:  Med Pediatr Oncol       Date:  1978

6.  Prevention of infections in the neutropenic patient.

Authors:  J Verhoef
Journal:  Clin Infect Dis       Date:  1993-11       Impact factor: 9.079

7.  Oral antibiotic prophylaxis in patients with cancer: a double-blind randomized placebo-controlled trial.

Authors:  P A Pizzo; K J Robichaud; B K Edwards; C Schumaker; B S Kramer; A Johnson
Journal:  J Pediatr       Date:  1983-01       Impact factor: 4.406

8.  Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection. A prospective cooperative study of gnotobiotic care in acute leukaemia patients. III: The quality of isolation and decontamination.

Authors:  J Dankert; W Gaus; H Gaya; D Krieger; G Linzenmeier; D van der Waaij
Journal:  Infection       Date:  1978       Impact factor: 3.553

9.  Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections.

Authors:  S J Weisman; F J Scoopo; G M Johnson; A J Altman; J J Quinn
Journal:  J Clin Oncol       Date:  1990-03       Impact factor: 44.544

10.  Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia.

Authors:  J C Wade; S C Schimpff; K A Newman; P H Wiernik
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.